Ibandronate Injection (Ibandronic Acid Sodium Hydrate)

Adult administration

Administer 3 mg intravenously every 3 months over 15-30 seconds.

This medication must be administered intravenously, and caution is advised as injecting into the arteries or around the veins may cause tissue damage. It should not be used in patients with allergy to this medication or its components or in patients with untreated hypocalcemia. During treatment, gastrointestinal adverse reactions such as gastritis, diarrhea, abdominal pain, dyspepsia, nausea, and constipation may occur, as well as musculoskeletal adverse reactions such as musculoskeletal pain, joint pain, and muscle pain. Additionally, during the initial administration, flu-like symptoms such as joint pain, muscle pain, fever, chills, fatigue, nausea, loss of appetite, and bone pain may temporarily occur, although they are mostly mild and resolve without treatment. This medication can temporarily lower serum calcium levels, so underlying conditions of hypocalcemia or bone and mineral metabolism disorders should be treated before administration, and adequate intake of calcium and vitamin D is important. Patients undergoing dental treatment or cancer patients may face a risk of jaw bone necrosis; therefore, an oral examination and preventive dental treatment are recommended before administration, and excessive dental treatment should be avoided during treatment. Rarely, osteonecrosis of the external auditory canal may occur in patients receiving this medication, so be cautious if there is pain or discharge from the ear. Long-term use may result in atypical fractures of the femur or other bones, so if there is pain in the thigh or groin, consult a physician immediately. This medication may cause serious allergic reactions or anaphylaxis; if abnormal symptoms occur during administration, discontinue immediately and seek appropriate treatment. Safety during pregnancy and lactation has not been established, so its use is not recommended. The risk of drug interactions with this medication is low, but it may affect kidney function; therefore, patients with kidney disease or those taking medications affecting the kidneys require regular monitoring. In the event of overdose, kidney and liver functions should be carefully monitored, and if any electrolyte abnormalities such as hypocalcemia occur, appropriate treatment should be administered. This medication must not be mixed with calcium-containing solutions and should only be administered intravenously with the designated solution. Keep out of reach of children, do not reuse needles and syringes, and dispose of safely after use.

Serious side effects

• Urticaria
• angioedema
• facial swelling/edema
• anaphylactic reactions/shock
• worsening of asthma
• Stevens-Johnson syndrome
• erythema multiforme
• bullous dermatitis
• acute renal failure
• respiratory distress

Mild side effects

• Gastritis
• diarrhea
• abdominal pain
• dyspepsia
• nausea
• constipation
• musculoskeletal pain
• joint pain
• muscle pain
• flu-like illness

This medication should be stored in a sealed container to prevent air and moisture exposure. It is important to maintain storage temperatures between 1 and 30 degrees Celsius. Proper storage will help maintain the drug's efficacy and safety.

Appearance

A colorless and transparent solution in a colorless and transparent glass prefilled syringe with a single-use needle attached.

Package unit

3 milliliters/prefilled syringe